A Phase 3 clinical trial evaluating guselkumab (Tremfya) for the treatment of juvenile psoriatic arthritis (jPsA) reached primary completion on 2026-01-12. This milestone indicates that data collection for the study's primary objectives has concluded.
Background
The study, titled 'A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis,' aims to evaluate the pharmacokinetics (PK), efficacy, safety, and immunogenicity of ustekinumab and guselkumab in pediatric participants with active juvenile psoriatic arthritis (jPsA).
Trial design
The study (NCT05083182) is a Phase 3 trial with an enrollment of 50 participants. It investigates the use of ustekinumab or guselkumab in pediatric participants diagnosed with active juvenile psoriatic arthritis.
What this means
The primary completion of this Phase 3 trial represents a significant step towards understanding the potential role of guselkumab in treating juvenile psoriatic arthritis. With primary data collection concluded, the focus will now shift to data analysis and the eventual reporting of results, which will provide insights into the efficacy and safety profile of the drug in this pediatric population.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05083182, titled 'A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis,' was posted on 2026-01-12 on clinicaltrials.gov.